{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:11:24Z","timestamp":1787724684964,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s43440-020-00103-4","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T16:02:30Z","timestamp":1586361750000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anxiolytic-like effects of mirogabalin, a novel ligand for \u03b12\u03b4 ligand of voltage-gated calcium channels, in rats repeatedly injected with acidic saline intramuscularly, as an experimental model of fibromyalgia"],"prefix":"10.1007","volume":"72","author":[{"given":"Hiroyasu","family":"Murasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Domon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"103_CR1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2014.3266","volume":"311","author":"DJ Clauw","year":"2014","unstructured":"Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547\u201355.","journal-title":"JAMA"},{"key":"103_CR2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3899\/jrheum.170095","volume":"44","author":"JN Ablin","year":"2017","unstructured":"Ablin JN, Wolfe F. A comparative evaluation of the 2011 and 2016 criteria for fibromyalgia. J Rheumatol. 2017;44:1271\u20136.","journal-title":"J Rheumatol"},{"key":"103_CR3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/ejp.1252","volume":"22","author":"MA Fitzcharles","year":"2018","unstructured":"Fitzcharles MA, Perrot S, H\u00e4user W. Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain. 2018;22:1565\u201376.","journal-title":"Eur J Pain"},{"key":"103_CR4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14656566.2015.1047343","volume":"16","author":"EP Calandre","year":"2015","unstructured":"Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16:1347\u201368.","journal-title":"Expert Opin Pharmacother"},{"key":"103_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/biomedicines5020020","volume":"5","author":"S Kia","year":"2017","unstructured":"Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5:20.","journal-title":"Biomedicines"},{"key":"103_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, Flu\u00df E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318\u201328.","journal-title":"Ann Rheum Dis"},{"key":"103_CR7","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","volume":"271","author":"NS Gee","year":"1996","unstructured":"Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the \u03b12\u03b4 subunit of a calcium channel. J Biol Chem. 1996;271:5768\u201376.","journal-title":"J Biol Chem"},{"key":"103_CR8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","volume":"28","author":"DJ Dooley","year":"2007","unstructured":"Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel \u03b12\u03b4 ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75\u201382.","journal-title":"Trends Pharmacol Sci"},{"key":"103_CR9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","volume":"667","author":"Z Li","year":"2011","unstructured":"Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, et al. Pregabalin is a potent and selective ligand for \u03b12\u03b4-1 and \u03b12\u03b4-2 calcium channel subunits. Eur J Pharmacol. 2011;667:80\u201390.","journal-title":"Eur J Pharmacol"},{"key":"103_CR10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.tips.2013.04.001","volume":"34","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: Is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013;34:332\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"103_CR11","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1113\/JP272262","volume":"594","author":"AC Dolphin","year":"2016","unstructured":"Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol. 2016;594:5369\u201390.","journal-title":"J Physiol"},{"key":"103_CR12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1517\/14656566.7.15.2139","volume":"7","author":"SA Montgomery","year":"2006","unstructured":"Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother. 2006;7:2139\u201354.","journal-title":"Expert Opin Pharmacother"},{"key":"103_CR13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"CP Taylor","year":"2007","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12-\u03b4 (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137\u201350.","journal-title":"Epilepsy Res"},{"key":"103_CR14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","volume":"28","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28:835\u201354.","journal-title":"CNS Drugs"},{"key":"103_CR15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79:463\u20138.","journal-title":"Drugs"},{"key":"103_CR16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306.","journal-title":"J Diabetes Investig"},{"key":"103_CR17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","volume":"160","author":"J Kato","year":"2019","unstructured":"Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160:1175\u201385.","journal-title":"Pain"},{"key":"103_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3844\/amjsp.2019.1.8","volume":"9","author":"LM Arnold","year":"2019","unstructured":"Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019;9:1\u201311.","journal-title":"Curr Med Res Opin"},{"key":"103_CR19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00210-019-01628-z","volume":"392","author":"K Saeki","year":"2019","unstructured":"Saeki K, Yasuda SI, Kato M, Kano M, Domon Y, Arakawa N, et al. Analgesic effects of mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:723\u20138.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"103_CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"103_CR21","first-page":"659","volume":"73","author":"Y Domon","year":"2018","unstructured":"Domon Y, Kitano Y, Makino M. Analgesic effects of the novel \u03b12\u03b4 ligand mirogabalin in a rat model of spinal cord injury. Pharmazie. 2018;73:659\u201361.","journal-title":"Pharmazie"},{"key":"103_CR22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00213-019-05356-3","volume":"237","author":"H Murasawa","year":"2020","unstructured":"Murasawa H, Kobayashi H, Saeki K, Kitano Y. Anxiolytic effects of the novel \u03b12\u03b4 ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain. Psychopharmacology. 2020;237:189\u201397.","journal-title":"Psychopharmacology"},{"key":"103_CR23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8","volume":"24","author":"KA Sluka","year":"2001","unstructured":"Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve. 2001;24:37\u201346.","journal-title":"Muscle Nerve"},{"key":"103_CR24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar4402","volume":"15","author":"JM DeSantana","year":"2013","unstructured":"DeSantana JM, da Cruz KM, Sluka KA. Animal models of fibromyalgia. Arthritis Res Ther. 2013;15:222.","journal-title":"Arthritis Res Ther"},{"key":"103_CR25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/17460441.2015.1066776","volume":"10","author":"Y Nagakura","year":"2015","unstructured":"Nagakura Y. Challenges in drug discovery for overcoming 'dysfunctional pain': an emerging category of chronic pain. Expert Opin Drug Discov. 2015;10:1043\u20135.","journal-title":"Expert Opin Drug Discov"},{"key":"103_CR26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpain.2006.11.007","volume":"8","author":"T Yokoyama","year":"2007","unstructured":"Yokoyama T, Maeda Y, Audette KM, Sluka KA. Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. J Pain. 2007;8:422\u20139.","journal-title":"J Pain"},{"key":"103_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","volume":"33","author":"GJ Bennett","year":"1988","unstructured":"Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87\u2013107.","journal-title":"Pain"},{"key":"103_CR28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12868-015-0150-x","volume":"16","author":"XQ Wang","year":"2015","unstructured":"Wang XQ, Zhong XL, Li ZB, Wang HT, Zhang J, Li F, et al. Differential roles of hippocampal glutamatergic receptors in neuropathic anxiety-like behavior after partial sciatic nerve ligation in rats. BMC Neurosci. 2015;16:14.","journal-title":"BMC Neurosci"},{"key":"103_CR29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejpain.2007.10.002","volume":"12","author":"M Benbouzid","year":"2008","unstructured":"Benbouzid M, Pallage V, Rajalu M, Waltisperger E, Doridot S, Poisbeau P, et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur J Pain. 2008;12:591\u20139.","journal-title":"Eur J Pain"},{"key":"103_CR30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.biopsych.2011.07.017","volume":"70","author":"I Yalcin","year":"2011","unstructured":"Yalcin I, Bohren Y, Waltisperger E, Sage-Ciocca D, Yin JC, Freund-Mercier MJ, et al. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol Psychiatry. 2011;70:946\u201353.","journal-title":"Biol Psychiatry"},{"key":"103_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.physbeh.2014.03.030","volume":"131","author":"YT Liu","year":"2014","unstructured":"Liu YT, Shao YW, Yen CT, Shaw FZ. Acid-induced hyperalgesia and anxio-depressive comorbidity in rats. Physiol Behav. 2014;131:105\u201310.","journal-title":"Physiol Behav"},{"key":"103_CR32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1744-8069-4-52","volume":"4","author":"M Nishiyori","year":"2008","unstructured":"Nishiyori M, Ueda H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol Pain. 2008;4:52.","journal-title":"Mol Pain"},{"key":"103_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","volume":"146","author":"Y Nagakura","year":"2009","unstructured":"Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain. 2009;146:26\u201333.","journal-title":"Pain"},{"key":"103_CR34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jphs.2016.01.002","volume":"131","author":"T Mukae","year":"2016","unstructured":"Mukae T, Fujita W, Ueda H. P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain. J Pharmacol Sci. 2016;131:64\u20137.","journal-title":"J Pharmacol Sci"},{"key":"103_CR35","doi-asserted-by":"crossref","first-page":"112506","DOI":"10.1016\/j.bbr.2020.112506","volume":"383","author":"T Iwai","year":"2020","unstructured":"Iwai T, Kikuchi A, Oyama M, Watanabe S, Tanabe M. Mirogabalin prevents repeated restraint stress-induced dysfunction in mice. Behav Brain Res. 2020;383:112506 (in press).","journal-title":"Behav Brain Res."},{"key":"103_CR36","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.neuroscience.2006.11.029","volume":"144","author":"FS Hasnie","year":"2007","unstructured":"Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-like behavior, and the influence of analgesic drugs. Neuroscience. 2007;144:1495\u2013508.","journal-title":"Neuroscience"},{"key":"103_CR37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.neulet.2008.10.005","volume":"448","author":"VC Wallace","year":"2008","unstructured":"Wallace VC, Segerdahl AR, Blackbeard J, Pheby T, Rice AS. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci Lett. 2008;448:153\u20136.","journal-title":"Neurosci Lett"},{"key":"103_CR38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pain.2008.05.003","volume":"139","author":"K Roeska","year":"2008","unstructured":"Roeska K, Doods H, Arndt K, Treede RD, Ceci A. Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. Pain. 2008;139:349\u201357.","journal-title":"Pain"},{"key":"103_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.brainres.2010.11.008","volume":"1370","author":"C Baastrup","year":"2011","unstructured":"Baastrup C, Jensen TS, Finnerup NB. Pregabalin attenuates place escape\/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2011;1370:129\u201335.","journal-title":"Brain Res"},{"key":"103_CR40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.pain.2012.04.023","volume":"153","author":"S Gr\u00e9goire","year":"2012","unstructured":"Gr\u00e9goire S, Michaud V, Chapuy E, Eschalier A, Ardid D. Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin. Pain. 2012;153:1657\u201363.","journal-title":"Pain"},{"key":"103_CR41","doi-asserted-by":"crossref","first-page":"e0150164","DOI":"10.1371\/journal.pone.0150164","volume":"11","author":"SE Harte","year":"2016","unstructured":"Harte SE, Meyers JB, Donahue RR, Taylor BK, Morrow TJ. Mechanical conflict system: a novel operant method for the assessment of nociceptive behavior. PLoS ONE. 2016;11:e0150164.","journal-title":"PLoS ONE"},{"key":"103_CR42","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ejp.868","volume":"20","author":"C La Porta","year":"2016","unstructured":"La Porta C, Lara-Mayorga IM, Negrete R, Maldonado R. Effects of pregabalin on the nociceptive, emotional and cognitive manifestations of neuropathic pain in mice. Eur J Pain. 2016;20:1454\u201366.","journal-title":"Eur J Pain"},{"key":"103_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0703794","volume":"132","author":"MJ Field","year":"2001","unstructured":"Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol. 2001;132:1\u20134.","journal-title":"Br J Pharmacol"},{"key":"103_CR44","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/jm049762l","volume":"48","author":"TR Belliotti","year":"2005","unstructured":"Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, et al. Structure-activity relationships of pregabalin and analogues that target the \u03b12-\u03b4 protein. J Med Chem. 2005;48:2294\u2013307.","journal-title":"J Med Chem"},{"key":"103_CR45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/jpet.111.180976","volume":"338","author":"SM Lotarski","year":"2011","unstructured":"Lotarski SM, Donevan S, El-Kattan A, Osgood S, Poe J, Taylor CP, et al. Anxiolytic-like activity of pregabalin in the Vogel conflict test in \u03b12\u03b4-1 (R217A) and \u03b12\u03b4-2 (R279A) mouse mutants. J Pharmacol Exp Ther. 2011;338:615\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"103_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","volume":"52","author":"B Gustorff","year":"2008","unstructured":"Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiol Scand. 2008;52:132\u20136.","journal-title":"Acta Anaesthesiol Scand"},{"key":"103_CR47","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.pain.2011.09.014","volume":"152","author":"N Attal","year":"2011","unstructured":"Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836\u201343.","journal-title":"Pain"},{"key":"103_CR48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/j.1532-2149.2013.00334.x","volume":"17","author":"F Radat","year":"2013","unstructured":"Radat F, Margot-Duclot A, Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. Eur J Pain. 2013;17:1547\u201357.","journal-title":"Eur J Pain"},{"key":"103_CR49","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/pme.12502","volume":"15","author":"C Schaefer","year":"2014","unstructured":"Schaefer C, Mann R, Sadosky A, Daniel S, Parsons B, Nieshoff E, et al. Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation. Pain Med. 2014;15:2105\u201319.","journal-title":"Pain Med"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00103-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-020-00103-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00103-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T17:47:15Z","timestamp":1722707235000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-020-00103-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00103-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HM, HK, SY, and KS are employees of Nihon Bioresearch Inc., while YD, NA, KK, and YK are employees of Daiichi Sankyo Co., Ltd. This study was sponsored by Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}